Literature DB >> 16769654

Survival, mortality and causes of death in inflammatory myopathies.

Carmen Torres1, Rebeca Belmonte, Loreto Carmona, F Javier Gómez-Reino, María Galindo, Belén Ramos, Ana Cabello, Patricia E Carreira.   

Abstract

OBJECTIVE: To investigate the causes of death, survival and clinical factors associated with mortality, in a group of Spanish patients with inflammatory myopathies (IM) followed in the same University Hospital during a 25 year period.
METHODS: A cross sectional study was performed, including 107 patients diagnosed with IM according to the Bohan and Peter criteria. Demographical and clinical information were extracted from the charts. Bivariate odds ratio with 95% confidence interval (CI) was used to measure the strength of association between variables. Kaplan-Meyer analysis was used to estimate survival. Univariate and multivariate Cox regression analysis were used to study clinical associations with mortality.
RESULTS: Twenty-eight patients (26%) died. Deaths were considered to be disease related in 21 cases. Main causes of death were cancer extension, cardiac involvement and lung involvement. Survival for the whole group was 92, 80 and 71% after 1, 5 and 10 years, respectively. By the log rank test, survival was lower for patients with cancer (p = 0.0001) as well as in those with cardiac involvement (p < 0.00001), compared to patients without these conditions. Cox univariate analysis showed that mortality was associated with higher age at IM onset, left ventricular dysfunction, the presence of cancer and the smoking habit. In Cox multivariate analysis, only left ventricular dysfunction (HR = 4.6; 95%CI 2.0-10.3; p > 0.0001) and the presence of cancer (HR = 3.3; 95%CI 1.4-7.4; p = 0.005) remained associated with mortality.
CONCLUSIONS: Although a great improvement has been achieved in the last decades in controlling IM, our study indicates that the mortality rate in this group of patients remains high. Cancer and cardiac involvement are important causes of death, and also prognostic factors for mortality in our group of patients. A careful search for cardiac involvement should be done in every patient with IM.

Entities:  

Mesh:

Year:  2006        PMID: 16769654     DOI: 10.1080/08916930600622603

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  31 in total

1.  Long-term follow-up of 62 patients with myositis.

Authors:  Janneke van de Vlekkert; Jessica E Hoogendijk; Marianne de Visser
Journal:  J Neurol       Date:  2014-05       Impact factor: 4.849

2.  Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease.

Authors:  Cheilonda Johnson; Iago Pinal-Fernandez; Radhika Parikh; Julie Paik; Jemima Albayda; Andrew L Mammen; Lisa Christopher-Stine; Sonye Danoff
Journal:  Lung       Date:  2016-05-11       Impact factor: 2.584

3.  Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study.

Authors:  Kyoko Motomura; Hiroyuki Yamashita; Saeko Yamada; Yuko Takahashi; Hiroshi Kaneko
Journal:  Rheumatol Int       Date:  2019-08-23       Impact factor: 2.631

4.  Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.

Authors:  Yizhi Xiao; Hui Luo; Bin Zhou; Xiaodan Dai; Jing Huang; Liping Duan; Yunhui You; Weiru Zhang; Hongjun Zhao; Yanli Xie; Yaou Zhou; Wangbin Ning; Tong Li; Sijia Liu; Honglin Zhu; Xiaoyun Xie; Ying Jiang; Shiyao Wu; Weijia He; Yisha Li
Journal:  Rheumatol Int       Date:  2016-11-22       Impact factor: 2.631

5.  Cardiac function in patients with polymyositis or dermatomyositis: a three-dimensional speckle-tracking echocardiography study.

Authors:  Yue Zhong; Wenjuan Bai; Qibing Xie; Jianhong Sun; Hong Tang; Li Rao
Journal:  Int J Cardiovasc Imaging       Date:  2017-11-22       Impact factor: 2.357

6.  Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain.

Authors:  Laura Nuño-Nuño; Beatriz Esther Joven; Patricia E Carreira; Valentina Maldonado-Romero; Carmen Larena-Grijalba; Irene Llorente Cubas; Eva Gloria Tomero; María Carmen Barbadillo-Mateos; Paloma García De la Peña Lefebvre; Lucía Ruiz-Gutiérrez; Juan Carlos López-Robledillo; Henry Moruno-Cruz; Ana Pérez; Tatiana Cobo-Ibáñez; Raquel Almodóvar González; Leticia Lojo; María Jesús García De Yébenes; Francisco Javier López-Longo
Journal:  Rheumatol Int       Date:  2017-09-02       Impact factor: 2.631

7.  Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis.

Authors:  M O Harris-Love; J A Shrader; D Koziol; N Pahlajani; M Jain; M Smith; H L Cintas; C L McGarvey; L James-Newton; A Pokrovnichka; B Moini; I Cabalar; D J Lovell; R Wesley; P H Plotz; F W Miller; J E Hicks; L G Rider
Journal:  Rheumatology (Oxford)       Date:  2008-12-11       Impact factor: 7.580

8.  Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients.

Authors:  Rohit Aggarwal; Elaine Cassidy; Noreen Fertig; Diane Carol Koontz; Mary Lucas; Dana P Ascherman; Chester V Oddis
Journal:  Ann Rheum Dis       Date:  2013-02-19       Impact factor: 19.103

9.  Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.

Authors:  Rohit Aggarwal; Andriy Bandos; Ann M Reed; Dana P Ascherman; Richard J Barohn; Brian M Feldman; Frederick W Miller; Lisa G Rider; Michael O Harris-Love; Marc C Levesque; Chester V Oddis
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

10.  Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up.

Authors:  K P Ng; F Ramos; S M Sultan; D A Isenberg
Journal:  Clin Rheumatol       Date:  2009-04-23       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.